Sol-Gel Technologies Ltd.SLGLEarnings & Financial Report
Sol-Gel Technologies Ltd. is a specialty biopharmaceutical company focused on developing and commercializing innovative dermatology treatments. Leveraging its proprietary sol-gel delivery technology, it creates topical therapies for common skin conditions including acne, rosacea and atopic dermatitis, with primary markets across North America and Europe, partnering with established healthcare firms to expand product reach.
SLGL Q2 FY2025 Key Financial Metrics
Revenue
$17.3M
Gross Profit
N/A
Operating Profit
$11.2M
Net Profit
$11.6M
Gross Margin
N/A
Operating Margin
65.1%
Net Margin
67.3%
YoY Growth
217.7%
EPS
$4.17
Sol-Gel Technologies Ltd. Q2 FY2025 Financial Summary
Sol-Gel Technologies Ltd. reported revenue of $17.3M (up 217.7% YoY) for Q2 FY2025, with a net profit of $11.6M (up 487.6% YoY) (67.3% margin).
Key Financial Metrics
| Total Revenue | $17.3M |
|---|---|
| Net Profit | $11.6M |
| Gross Margin | N/A |
| Operating Margin | 65.1% |
| Report Period | Q2 FY2025 |
Sol-Gel Technologies Ltd. Quarterly Revenue & Net Profit History
Sol-Gel Technologies Ltd. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $17.3M | +217.7% | $11.6M | 67.3% |
| Q2 FY2024 | $5.4M | +814.6% | $2.0M | 36.4% |
| Q2 FY2023 | $594.0K | -83.1% | $-6.0M | -1005.1% |
| Q2 FY2022 | $3.5M | +279.1% | $-134.0K | -3.8% |
Income Statement
| Q2 2022 | Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|---|
| Revenue | $3.5M | $594000 | $5.4M | $17.3M |
| YoY Growth | 279.1% | -83.1% | 814.6% | 217.7% |
Balance Sheet
| Q2 2022 | Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|---|
| Assets | $55.0M | $55.1M | $42.0M | $39.3M |
| Liabilities | $4.6M | $6.8M | $7.1M | $7.4M |
| Equity | $50.4M | $48.3M | $34.9M | $31.9M |
Cash Flow
| Q2 2023 | |
|---|---|
| Operating CF | $-8.3M |